The research compound in Ozempic®
Ozempic® is a type 2 diabetes medicine from Novo Nordisk. Its active compound is Semaglutide — which is what this catalogue supplies, as a research material.
This is not Ozempic®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Semaglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Ozempic® is a trademark of Novo Nordisk, referenced here only to identify the compound.
Ozempic is Novo Nordisk’s brand for injectable semaglutide in type 2 diabetes. The same compound is sold as Wegovy for weight management and as Rybelsus in tablet form.
Semaglutide is a GLP-1 receptor agonist whose structural modifications — a C18 di-acid chain and a spacer — give it a half-life of roughly seven days, the basis for once-weekly dosing.
This catalogue supplies semaglutide as a research material. It is not Ozempic and is not intended for human use.
Semaglutide in this catalogue
0.25mg × 4 pens
How Semaglutide is supplied here
Everything below describes the research material in this catalogue, not the medicine. Semaglutide is stocked in 3 presentations, so the figures below are for the base one.
| Compound | Semaglutide |
|---|---|
| Presentation | 0.25mg × 4 pens |
| Dosage options | 0.25mg × 4 pens · 1mg × 4 pens · 2.4mg × 4 pens |
| Research category | Metabolic Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Ozempic?
Semaglutide. Ozempic is a registered trademark of Novo Nordisk, approved for type 2 diabetes.
Is this Ozempic?
No. NOVALYTE LABS supplies Semaglutide as a research material with batch documentation. It is not Ozempic, it is not a medicine, it is not supplied for human use, and there is no affiliation with Novo Nordisk.
Why is Semaglutide sold under more than one brand?
Because a brand is tied to an approved indication rather than to the molecule. Semaglutide is marketed as Ozempic and also as Wegovy — same compound, different approvals.
Other brands using Semaglutide
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.